Novo Nordisk Investing $73M in Clayton, North Carolina, Facility
10/04/2010
"The investment to expand our Clayton facility is another example of our commitment to improving diabetes treatment options in the U.S. by ensuring patients have access to the latest advances in treatment," said Jerzy Gruhn, president of Novo Nordisk Inc. "Insulin delivery devices give people with diabetes a convenient way to manage their health and engage in a productive lifestyle. As patients in the U.S. continue to move from administering insulin with a conventional vial and syringe to using a pen device, Novo Nordisk will be prepared to meet growing market demand."
The facility produces Novo Nordisk products including the Levemir FlexPen. The expansion will add two final assembly lines, two packing lines, along with refurbishing the building.
Cost and productivity factors, including state and local incentives, helped Novo Nordisk choose Clayton. The company has been approved for Job Development Investment Grant funds, as well as a $400,000 One North Carolina Fund grant.
Project Announcements
Route 92 Medical Plans West Jordan, Utah, Operations
03/21/2026
Southwark Metal Manufacturing Company Plans Hernando, Mississippi, Operations
03/21/2026
Cheney Brothers Expands Florence, South Carolina, Distribution Operations
03/20/2026
Create Energy Expands-Plans Sumner County-Robertson County, Tennessee, Operations
03/20/2026
United Kingdom-Based Dechra Plans Boston, Massachusetts, Headquarters Operations
03/20/2026
France-Based Bel Group Expands Brookings, South Dakota, Production Operations
03/20/2026
Most Read
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024
-
What Companies Need from Modern Manufacturing Sites
Q1 2026
-
Economic Developer Role Shifting from Deal-Making to Systems Stewardship
Q1 2026
-
Capitalizing on the OBBBA Before the 2026 Cliff
Q1 2026
-
The Skilled Trades Are Ready for a Digital Future
Q4 2025
-
Amazon’s First Mass Timber Delivery Station Tests the Future of Low-Carbon Logistics
Q4 2025
-
Last Word: Don’t Lose by Winning
Q1 2026